Text Size
20 studies found for:    "Lymphangioleiomyomatosis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed
Has Results 		Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Conditions: Lymphangioleiomyomatosis;   Lymphangiomyomas;   Pleural Effusions;   Ascites
Intervention: Drug: Octreotide
2 Completed Pulmonary Hypertension in Lymphangioleiomyomatosis
Conditions: Lymphangioleiomyomatosis;   Pulmonary Hypertension
Intervention:
3 Not yet recruiting National Lymphangioleiomyomatosis Registry, France
Condition: Lymphangioleiomyomatosis
Intervention:
4 Completed A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Drug: Everolimus
5 Unknown † Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
Condition: Lymphangioleiomyomatosis
Interventions: Drug: Sirolimus;   Drug: Placebo sirolimus
6 Recruiting Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: albuterol inhaler;   Procedure: PFT;   Drug: albuterol nebulizer
7 Unknown † Trial of Aromatase Inhibition in Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: Letrozole;   Drug: Placebo
8 Active, not recruiting Doxycycline In Lymphangioleiomyomatosis (LAM)
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis
Interventions: Drug: Doxycycline;   Drug: Placebo
9 Active, not recruiting
Has Results 		Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Conditions: Tuberous Sclerosis Complex (TSC);   Lymphangioleiomyomatosis (LAM)
Interventions: Drug: Everolimus (RAD001);   Other: Placebo
10 Recruiting Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Drug: sirolimus and hydroxychloroquine
11 Completed Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Conditions: Lymphangioleiomyomas;   Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention:
12 Unknown † Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention: Drug: sirolimus
13 Completed Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention: Drug: Rapamycin, sirolimus
14 Active, not recruiting RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis
Intervention: Drug: RAD001
15 Completed Lymphangioleiomyomatosis (LAM) Registry
Conditions: Lung Diseases;   Lymphangiomyomatosis
Intervention:
16 Recruiting Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Conditions: Pulmonary Disease;   Oropharyngeal Disease;   Lymphangioleiomyomatosis;   Pulmonary Fibrosis;   Asthma;   Sarcoidosis
Intervention:
17 Recruiting Study of the Disease Process of Lymphangioleiomyomatosis
Conditions: Lung Disease;   Pneumothorax;   Tuberous Sclerosis
Intervention:
18 Completed Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)
Condition: Leiomyomatosis
Intervention:
19 Active, not recruiting Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
Conditions: Tuberous Sclerosis;   Angiolipoma
Intervention: Drug: everolimus (RAD001)
20 Active, not recruiting Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Conditions: Kaposiform Hemangioendotheliomas;   Tufted Angioma;   Capillary Venous Lymphatic Malformation;   Venous Lymphatic Malformation;   Microcystic Lymphatic Malformation;   Mucocutaneous Lymphangiomatosis and Thrombocytopenia;   Capillary Lymphatic Arterial Venous Malformations;   PTEN Overgrowth Syndrome With Vascular Anomaly;   Lymphangiectasia Syndromes
Intervention: Drug: sirolimus
To Top

† Indicates status has not been verified in more than two years